IDEAYA Biosciences berencana untuk memulai uji coba klinis Fase 3 untuk IDE849, obat kanker paru-paru sel kecil stadium lanjut (ES-SCLC), pada akhir tahun 2026. Keputusan ini menyusul pertemuan positif dengan FDA mengenai desain uji coba. Uji coba ini akan mengevaluasi IDE849 sebagai monoterapi dengan tujuan mendapatkan persetujuan yang dipercepat berdasarkan tingkat respons keseluruhan dan persetujuan penuh berdasarkan kelangsungan hidup keseluruhan rata-rata. Perusahaan juga akan menyajikan data klinis terbaru untuk IDE849 pada akhir tahun 2026.
Oppenheimer & Co. Inc. announced that Joel Berry II, a former college basketball star and professional player, has joined its Robinson Private Client Group as a Financial Advisor. Berry will focus on advising current and former athletes, including st...
So-Young International Inc. posted a 33.4% increase in total revenues to RMB505.2 million in Q2 2026, led by a 129.5% surge in aesthetic treatment services revenue. The company narrowed its net loss to RMB22.7 million from RMB36.0 million a year earl...
Primary Hydrogen Corp. has secured four exploration licences totaling 1,101 hectares for the Wallace Natural Hydrogen Project in Nova Scotia's Cumberland Basin, expanding its holdings to six licences in the area. The project area includes significant...
Jazz Pharmaceuticals announced positive results from its HERIZON-GEA-01 trial, showing that Ziihera, combined with chemotherapy, significantly improved overall survival in adults with HER2-positive gastroesophageal adenocarcinoma (GEA) compared to th...
Hannan Metals announced strong assay results from its first drill program at the Stavaträsk gold project in northern Sweden, confirming gold mineralization in all seven holes over 650 meters of strike. The deepest hole, ST2606, returned the best inte...
